Syros Pharmaceuticals (SYRS) Reiterated at Buy by Brookline Capital Markets, Sees Additional Upside from CDK12
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $23.00 price target on Syros Pharmaceuticals (NASDAQ: SYRS) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
